IONIS PHARMACEUTICALS INC
IONIS-MAPT Rx
Alzheimer’s disease
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for IONIS-MAPT Rx in Alzheimer’s disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“Multiple Phase 2 data readouts , including IONIS-MAPT Rx (BIIB 0 80) in Alzheimer’s disease (AD) (Biogen)”